Turning Point Therapeutics, Inc. Stock-Based Compensation
Turning Point Therapeutics, Inc. reported Stock-Based Compensation of $32.40 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2022-08-08
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2022-06-30 was $17.31M, a 30.21% increase year-over-year.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2022-03-31 was $15.09M, a 12.67% decline year-over-year.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2021-12-31 was $14.19M, a 44.35% increase year-over-year.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2021-09-30 was $13.79M, a 61.07% increase year-over-year.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2021 was $58.56M, a 8.74% decline from fiscal 2020.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2020 was $64.16M, a 404.98% increase from fiscal 2019.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2019 was $12.71M, a 1007.76% increase from fiscal 2018.
- Turning Point Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2018 was $1.15M, a 233.43% increase from fiscal 2017.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $17.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $32.40M 10-Q · filed 2022-08-08 | $46.59M derived: sum of 3 quarters · filed 2022-08-08 | $60.38M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $15.09M 10-Q · filed 2022-05-10 | $29.28M derived: sum of 2 quarters · filed 2022-05-10 | $43.07M derived: sum of 3 quarters · filed 2022-05-10 | $56.37M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | $14.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $27.98M derived: sum of 2 quarters · filed 2022-02-28 | $41.28M derived: sum of 3 quarters · filed 2022-08-08 | $58.56M 10-K · filed 2022-02-28 |
| 2021-09-30 | $13.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $27.09M derived: sum of 2 quarters · filed 2022-08-08 | $44.37M 10-Q · filed 2021-11-09 | $54.20M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | $13.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $30.57M 10-Q · filed 2022-08-08 | $40.40M derived: sum of 3 quarters · filed 2022-08-08 | $48.97M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $17.28M 10-Q · filed 2022-05-10 | $27.11M derived: sum of 2 quarters · filed 2022-05-10 | $35.67M derived: sum of 3 quarters · filed 2022-05-10 | $43.08M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $9.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $18.39M derived: sum of 2 quarters · filed 2022-02-28 | $25.80M derived: sum of 3 quarters · filed 2022-02-28 | $64.16M 10-K · filed 2022-02-28 |
| 2020-09-30 | $8.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $15.97M derived: sum of 2 quarters · filed 2021-11-09 | $54.33M 10-Q · filed 2021-11-09 | $58.56M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $7.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $45.77M 10-Q · filed 2021-08-09 | $50.00M derived: sum of 3 quarters · filed 2022-02-28 | $53.49M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $38.37M 10-Q · filed 2021-05-05 | $42.59M derived: sum of 2 quarters · filed 2022-02-28 | $46.09M derived: sum of 3 quarters · filed 2022-02-28 | $49.15M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $7.72M derived: sum of 2 quarters · filed 2022-02-28 | $10.78M derived: sum of 3 quarters · filed 2022-02-28 | $12.71M 10-K · filed 2022-02-28 |
| 2019-09-30 | $3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $6.55M derived: sum of 2 quarters · filed 2020-11-12 | $8.48M 10-Q · filed 2020-11-12 | $9.22M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $4.99M 10-Q · filed 2020-08-10 | $5.73M derived: sum of 3 quarters · filed 2021-03-01 | $5.91M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.93M 10-Q · filed 2020-05-12 | $2.67M derived: sum of 2 quarters · filed 2021-03-01 | $2.85M derived: sum of 3 quarters · filed 2021-03-01 | $2.99M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $746.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $925.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.06M derived: sum of 3 quarters · filed 2021-03-01 | $1.15M 10-K · filed 2021-03-01 |
| 2018-09-30 | $179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $316.00K derived: sum of 2 quarters · filed 2019-11-04 | $401.00K 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $222.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $85.00K 10-Q · filed 2019-05-31 | |||
| 2017-12-31 | $344.00K 10-K · filed 2020-03-18 |